Form 4: Theravance Biopharma CEO Rick Winningham Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Rick Winningham, CEO of Theravance Biopharma, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On February 20, 2025, Rick E Winningham, CEO of Theravance Biopharma, disposed of 35,129 ordinary shares to satisfy tax obligations.
- The shares were withheld by the issuer at a price of $9.66 per share.
- Following the transaction, Winningham directly owns 1,775,966 ordinary shares.
- Winningham also indirectly owns 3,900 shares as custodian and 92,567 shares through a trust.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing regarding share disposal for tax purposes, with neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the disposal of shares by the CEO.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of share disposal transaction. |
| 02/24/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Theravance Biopharma, TBPH, Rick Winningham, SEC Form 4, Beneficial Ownership, Share Disposal, Tax Obligations, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.